Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
eviQ 333: advanced pancreatic cancer gemcitabine
Product / population
Adult locally advanced/metastatic pancreatic cancer single-agent protocol; not all gemcitabine combinations.
Current retrieved protocol; kidney recommendations reference ADDIKD.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Gemcitabine: initial CKD guidance does not cancel a toxicity stop rule
eviQ supplies an initial indexed-eGFR approach for advanced pancreatic cancer. GEMZAR separately requires stopping for HUS or severe renal toxicity. These address different clinical states rather than permission to continue despite new injury.
What to reconcile: Establish baseline stability versus new drug-associated injury, indication and concomitant agents. Preserve the full toxicity monitoring and stop instructions.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
This protocol uses gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days, subject to its toxicity criteria. The kidney table retains full dose at eGFR >=60 and at 45-59, 30-44 and 15-29, with increased adverse-event risk flagged for the impaired bands. Below 15 without kidney replacement, or during replacement therapy, consult a multidisciplinary oncology/nephrology/clinical-pharmacology team. These initial CKD recommendations do not cancel a drug-induced HUS or severe-toxicity stop rule. Hematologic and other dose modifications remain separate.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.